Biotinylated Human APRIL CAR Detection Reagent, Fc, Avi-tag (CARD-LX144)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Evaluating CAR expression is an essential step in the production of CAR-T cells. Creative biolabs provides several detection reagents which are uniquely suitable for evaluation of CAR expression. Biotinylated Human APRIL CAR Detection Reagent, Fc,Avitag™ is a special detection reagent which is used to detect Human APRIL CAR related to the study of hematologic malignancies.

Specific Inquiry

  • Size:
  • Form:
  Add to Cart

Specifications

  • Target
  • APRIL
  • Application
  • FC, ELISA
  • Purity
  • >90%
  • Endotoxin Level
  • Less than 1.0 EU per μg by the LAL method.
  • Storage
  • For long term storage, the product should be stored at lyophilized state at -20°C or lower.
    Please protect from light and avoid repeated freeze-thaw cycles.
  • Application Notes
  • The optimal working dilutions should be determined by the end user.
  • Diseases
  • hematologic malignancies
  • Molecular Characterization
  • It contains AA Ala 105 - Leu 250 (Accession # O75888-1).
  • Conjugation
  • Biotinylated
  • Tag
  • Fc, Avi-tag
  • Size
  • 200ug
  • Formulation
  • Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
  • Expression
  • Human HEK293 cells
  • Host Species
  • Human
  • Species Reactivity
  • Human
  • Form
  • lyophilized

Target

  • Target Introduction
  • APRIL(a proliferation-inducing ligand) is also known as Tumor necrosis factor ligand superfamily member 13, TALL-2, TRDL-1, CD256, TNFFSF 13, cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. APRIL is a cytokine of the tumor necrosis factor family associated mainly with hematologic malignancies. The closely related TNF family ligands B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) serve in the generation and maintenance of mature B-lymphocytes. Both BAFF and APRIL assemble as homotrimers that bind and activate several receptors that they partially share. BAFF-APRIL heteromers of different stoichiometries have distinct receptor-binding properties and activities. In addition, expression of APRIL was regulated by miR-145 in GC cells.
  • Target Alternative Names
  • APRIL

Customer Reviews and Q&As

There are currently no customer reviews or questions for Biotinylated Human APRIL CAR Detection Reagent, Fc, Avi-tag (CARD-LX144). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.